Abstract: This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype. Treatment involves the use of radiation and a CD47-binding agent, preferably a CD47-binding form of human signal regulatory protein alpha (SIRPa) that inhibits activation of the CD47/SIRPa axis and mediates phagocytosis of CD47+ disease cells. An anti-cancer effect of a CD47 blocking agent is enhanced when combined with radiation therapy. The anti-cancer effect of a CD47 blocking agent such as SIRPaFc is enhanced when combined with radiation therapy.

Abstract: Subjects responsive to a CD47 blocking agent, such as SIRP?Fc, exhibit an elevated level of expression of one or more markers. Accordingly, subjects with elevated levels of the markers are treated with CD47 blocking agents while subject that are not responsive and 5 do not have elevated levels of markers are not selected for treatment. The markers are selected from CHIT1, SPP1, FC?R3A and FC?R2A.

Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRP?Fc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRP?Fc. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.

Abstract: This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype. Treatment involves the use of radiation and a CD47-binding agent, preferably a CD47-binding form of human signal regulatory protein alpha (SIRPa) that inhibits activation of the CD47/SIRPa axis and mediates phagocytosis of CD47+ disease cells. An anti-cancer effect of a CD47 blocking agent is enhanced when combined with radiation therapy. The anti-cancer effect of a CD47 blocking agent such as SIRPaFc is enhanced when combined with radiation therapy.

Abstract: CD47+ disease cells, such as various cancers, are treated using a combination of CD47 blockade with T cell checkpoint inhibition. Preferred embodiments use SIRP?Fc in combination with a PD-1 pathway inhibitor such as nivolumab and/or a CTLA-4 inhibitor such as ipilimumab.

Abstract: Blockade of the CD47/SIRPa pathway depletes cancer cells. This anti-cancer activity is enhanced when macrophage stimulating agents are used in combination with the CD47 blockade drug. This anti-cancer combination therapy is particularly effective when the CD47 blockade drug is SIRPaFc.